NeuroSense Therapeutics (NRSN) Competitors $1.00 -0.05 (-4.33%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$1.00 +0.00 (+0.40%) As of 03/28/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. OCX, CNTX, TNXP, PEPG, ALVR, MRSN, VTVT, KPTI, IMRX, and ONCYShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include OncoCyte (OCX), Context Therapeutics (CNTX), Tonix Pharmaceuticals (TNXP), PepGen (PEPG), AlloVir (ALVR), Mersana Therapeutics (MRSN), vTv Therapeutics (VTVT), Karyopharm Therapeutics (KPTI), Immuneering (IMRX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. OncoCyte Context Therapeutics Tonix Pharmaceuticals PepGen AlloVir Mersana Therapeutics vTv Therapeutics Karyopharm Therapeutics Immuneering Oncolytics Biotech NeuroSense Therapeutics (NASDAQ:NRSN) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking. Do analysts prefer NRSN or OCX? OncoCyte has a consensus target price of $4.56, indicating a potential upside of 42.13%. Given OncoCyte's stronger consensus rating and higher probable upside, analysts clearly believe OncoCyte is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community favor NRSN or OCX? OncoCyte received 9 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 9.91% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% OncoCyteOutperform Votes119.91%Underperform Votes10090.09% Do institutionals & insiders hold more shares of NRSN or OCX? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OncoCyte shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 1.6% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, NRSN or OCX? NeuroSense Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Which has higher valuation & earnings, NRSN or OCX? NeuroSense Therapeutics has higher earnings, but lower revenue than OncoCyte. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.64-1.55OncoCyte$1.88M29.78-$27.78M-$4.40-0.73 Does the media prefer NRSN or OCX? In the previous week, OncoCyte had 16 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 17 mentions for OncoCyte and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.94 beat OncoCyte's score of 0.31 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Overall Sentiment NeuroSense Therapeutics Positive OncoCyte Neutral Is NRSN or OCX more profitable? NeuroSense Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. NeuroSense Therapeutics' return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -590.79% OncoCyte -6,122.29%-269.32%-59.71% SummaryOncoCyte beats NeuroSense Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.60M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-1.557.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book-7.116.396.894.23Net Income-$11.28M$142.12M$3.20B$247.15M7 Day Performance-7.01%-5.06%-2.98%-2.17%1 Month Performance-10.16%-7.49%1.63%-5.68%1 Year Performance-45.33%-10.91%9.44%-0.74% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics0.7908 of 5 stars$1.00-4.3%N/A-45.3%$13.60MN/A-1.5510Upcoming EarningsOCXOncoCyte2.55 of 5 stars$3.33-2.1%$4.42+32.6%+9.6%$58.12M$709,000.000.00120Earnings ReportAnalyst ForecastShort Interest ↑CNTXContext Therapeutics2.1154 of 5 stars$0.76-1.0%$6.17+707.2%-52.5%$57.30MN/A-0.847Gap UpTNXPTonix Pharmaceuticals2.4536 of 5 stars$30.51+32.5%$585.00+1,817.4%-96.6%$57.02M$10.09M-0.0150Short Interest ↑Gap DownHigh Trading VolumePEPGPepGen2.3428 of 5 stars$1.70-4.0%$10.33+507.8%-89.9%$55.58MN/A-0.5730ALVRAlloVir2.1948 of 5 stars$11.00-3.5%N/A-48.1%$55.47MN/A-0.54110Positive NewsGap DownHigh Trading VolumeMRSNMersana Therapeutics4.386 of 5 stars$0.44+4.6%$4.00+799.3%-91.5%$55.44M$40.50M-0.73150Short Interest ↓Positive NewsVTVTvTv Therapeutics1.8221 of 5 stars$17.37+4.4%$35.00+101.5%-26.3%$55.41M$1.02M-3.839Analyst ForecastKPTIKaryopharm Therapeutics3.6424 of 5 stars$6.51+1.4%$57.50+783.3%-81.6%$54.80M$145.24M-6.38380Positive NewsIMRXImmuneering3.2967 of 5 stars$1.74-3.3%$11.00+532.2%-43.3%$54.03M$320,000.00-0.8860Short Interest ↓Analyst RevisionONCYOncolytics Biotech1.9902 of 5 stars$0.63-0.1%$4.00+535.6%-43.4%$53.81MN/A-2.3330Positive News Remove Ads Related Companies and Tools Related Companies OCX Competitors CNTX Competitors TNXP Competitors PEPG Competitors ALVR Competitors MRSN Competitors VTVT Competitors KPTI Competitors IMRX Competitors ONCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRSN Stock Free NRSN Stock Alerts